Non-Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Biological Adaptations of Strength Training to Obese and Normal Weight Middle-aged Men
Verified date | October 2023 |
Source | Democritus University of Thrace |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A two-trial repeated measures design will be employed in this investigation. Both the control trial and the exercise trial will last for 3 months. During a week before the start of the study, participants will complete dietary recalls and record their habitual physical activity using accelerometers. Thereafter, body composition, ultrasound imaging of the muscle and liver, biochemical and hematological markers were measured. This range of measurements will be repeated the ended each month for both trials. Control trial succeeds exercise trial. An exercise intervention program will take place in the second trial, three times a week.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 31, 2023 |
Est. primary completion date | December 25, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 35 Years to 50 Years |
Eligibility | Inclusion Criteria: - no use of medication - free of musculoskeletal limitations - absence of a known condition or medical condition preventing participation in the program (e.g. hypertension) - absence of a severe family medical history up to first degree relatives with cardiovascular disease and /or diabetes at the age of less than 65 for women and less than 55 years for men - non-smokers Exclusion Criteria: - use of medication - musculoskeletal limitations that will prevent participation in the training program - known condition or medical condition preventing participation in the program (e.g. hypertension) - a severe family medical history up to first degree relatives with cardiovascular disease and /or diabetes at the age of less than 65 for women and less than 55 years for men - smoking |
Country | Name | City | State |
---|---|---|---|
Greece | Democritus University of Thrace, School of Physical Education and Sports Science | Komotini |
Lead Sponsor | Collaborator |
---|---|
Democritus University of Thrace |
Greece,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in body composition | Body composition will be assessed using Dual-energy-X-ray Absorptiometry (DXA) instrumentation | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in HDL concentration | HDL concentration will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in LDL concentration | LDL concentration will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in total cholesterol | Total cholesterol levels will measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in triglycerides | Triglycerides concentration will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in free fatty acids | Free fatty acid concentration will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in glucose | Glucose concentration will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in glycosylated hemoglobin | Glycosylated hemoglobin levels will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in insulin | Insulin concentration will be measured in blood | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in insulin resistance index | Insulin resistance index will be calculated through glucose and insulin values | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in White Blood Cells | White blood cells will be measured in bood samples | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in Red Blood Cells | Red blood cells will be measured in bood samples | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in Hemoglobin | Hemoglobin will be measured in blood samples | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in Hematocrit | Hematocrit levels will be measured in blood samples | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in transaminases | Transaminase levels will be measured in blood samples | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in C-reactive protein | C-reactive protein levels will be measured in blood samples | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in total antioxidant capacity | Total antioxidant capacity will be assessed in plasma | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in glutathione | Oxidized (GSH) and reduced (GSSG) glutathione will be measured in red blood cell lysate | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in protein carbonyls | Protein carbonyl formation will be measured in serum | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in thiobarbituric acid reactive substances (TBARS) | TBARS will be measured in serum | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in catalase | Catalase activity will be measured in serum | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in fatty infiltration of the liver | Fatty infiltration of the liver will be assessed by ultrasound imaging of liver | At baseline as well as at 1,5 and 3 months in both trials | |
Primary | Changes in bone status | Bone mineral density and bone mineral content will be assessed in hole body, spine and hips using DXA | At baseline as well as at 1,5 and 3 months in both trials | |
Secondary | Changes in body weight | At baseline as well as at 1,5 and 3 months in both trials | ||
Secondary | Changes in muscle architecture | Muscle architecture of quadriceps will be assessed by ultrasonography | At baseline as well as at 1,5 and 3 months in both trials |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |